2022
Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study
Ward C, Phillips A, Oresanya O, Olisenekwu G, Arogunade E, Moukénet A, Beakgoubé H, De Paul Allambademel V, Compaoré C, Traoré A, Ouedraogo J, Compaoré Y, Zongo I, Donovan L, Decola M, Smith H, Baker K. Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study. Malaria Journal 2022, 21: 103. PMID: 35331248, PMCID: PMC8943494, DOI: 10.1186/s12936-022-04091-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyIPC measuresMalaria chemopreventionInfection preventionMethodsA cross-sectional studyEnhanced infection preventionSeasonal malaria chemopreventionCoronavirus disease 2019 (COVID-19) transmissionHigh malaria transmissionOptimal hand hygiene practicesHand hygiene practicesProportion of indicationsCOVID-19 pandemicEarly community engagementFirst doseHand hygieneWHO guidanceMalaria transmissionBurkina FasoHand washingControl measuresHygiene practicesProtective equipmentAdherenceBlister packs
2020
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
Zhang AD, Puthumana J, Downing NS, Shah ND, Krumholz HM, Ross JS. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. JAMA Network Open 2020, 3: e203284. PMID: 32315070, PMCID: PMC7175081, DOI: 10.1001/jamanetworkopen.2020.3284.Peer-Reviewed Original ResearchConceptsPivotal trialsProportion of indicationsIndication approvalsNew drugsUS FoodTrial durationPrimary end pointTherapeutic areasPivotal efficacy trialsCross-sectional studyDrug Administration approvalFast track designationCommon therapeutic areasRecent FDA approvalOrphan designationLonger trial durationAccelerated approvalAdministration approvalClinical trialsMonths durationEfficacy trialsMAIN OUTCOMETherapeutic safetyDrug AdministrationFDA approval
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply